Gilead Sciences, Inc. (NASDAQ:GILD) Receives Upgrade from BMO Capital

Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company renowned for its groundbreaking treatments in areas such as HIV, liver diseases, and cancer. BMO Capital recently upgraded its rating for GILD to "Outperform," signaling strong confidence in the company's future performance. At the time of this announcement, GILD was trading at $125.27.The upgrade by BMO Capital is primarily attributed to the exceptional performance of Gilead's HIV division. The company's third-quarter results exceed ...